Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pharmaceutical statistics

Showing results (1-10 of 1,233) with videos related to

Pageof 124
Sort By:
Pharmaceutical Statistics|December 13, 2022
On implementing Jeffreys' substitution likelihood for Bayesian inference concerning the medians of unknown distributionsAndrew P Grieve
Pharmaceutical Statistics|October 24, 2020
Defining estimands using a mix of strategies to handle intercurrent events in clinical trialsYongming Qu, Linda Shurzinske, Shanthi Sethuraman
Pharmaceutical Statistics|June 22, 2021
Comments on "Equal-tailed confidence intervals for comparison of rates"Yongqiang Tang
Pharmaceutical Statistics|January 6, 2023
Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studiesAndrea Callegaro, Naveen Karkada, Emmanuel Aris, et al.
Pharmaceutical Statistics|January 10, 2023
Bayesian hierarchical models for adaptive basket trial designsChian Chen, Chin-Fu Hsiao
Pharmaceutical Statistics|December 27, 2022
Improving early phase oncology clinical trial design: An opportunity for statisticiansAlan Phillips, Shalini Mondal
Pharmaceutical Statistics|June 23, 2022
Propensity score matching and stratification using multiparty data without poolingJixian Wang, Roland Marion-Gallois
Pharmaceutical Statistics|June 29, 2022
Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its componentsRan Liao, Sujatro Chakladar, Margaret Gamalo
Pharmaceutical Statistics|June 27, 2022
Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomesGaohong Dong, Bo Huang, Johan Verbeeck, et al.
Pharmaceutical Statistics|July 12, 2022
The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacyStephen Senn
Pageof 124

Showing results (1-10 of 1,233) with videos related to

Sort By:
Pageof 124
Pharmaceutical Statistics|December 13, 2022
On implementing Jeffreys' substitution likelihood for Bayesian inference concerning the medians of unknown distributionsAndrew P Grieve
Pharmaceutical Statistics|October 24, 2020
Defining estimands using a mix of strategies to handle intercurrent events in clinical trialsYongming Qu, Linda Shurzinske, Shanthi Sethuraman
Pharmaceutical Statistics|June 22, 2021
Comments on "Equal-tailed confidence intervals for comparison of rates"Yongqiang Tang
Pharmaceutical Statistics|January 6, 2023
Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studiesAndrea Callegaro, Naveen Karkada, Emmanuel Aris, et al.
Pharmaceutical Statistics|January 10, 2023
Bayesian hierarchical models for adaptive basket trial designsChian Chen, Chin-Fu Hsiao
Pharmaceutical Statistics|December 27, 2022
Improving early phase oncology clinical trial design: An opportunity for statisticiansAlan Phillips, Shalini Mondal
Pharmaceutical Statistics|June 23, 2022
Propensity score matching and stratification using multiparty data without poolingJixian Wang, Roland Marion-Gallois
Pharmaceutical Statistics|June 29, 2022
Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its componentsRan Liao, Sujatro Chakladar, Margaret Gamalo
Pharmaceutical Statistics|June 27, 2022
Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomesGaohong Dong, Bo Huang, Johan Verbeeck, et al.
Pharmaceutical Statistics|July 12, 2022
The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacyStephen Senn
Pageof 124